List view / Grid view
Filter the results
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
A study has shown that unintended mutations from gene editing with CRISPR-Cas9 are rare in zebrafish, providing reassurance that this technology is a valid tool with great promise for the treatment of genetic disorders.
New cell experiments show more effective genetic 'cuts' that could one day become the foundation of more effective gene therapies.
'Prime editing', a new CRISPR genome-editing approach, is capable of directly editing human cells in an accurate and efficient way.
Researchers have developed CRISPR-Cas13 enzyme-based technology that can be programmed to both detect and destroy RNA-based viruses in human cells.
A study has demonstrated how to use CRISPR to deliver DNA to particular bacteria, which could be used as an alternative to antibiotics.
The newly identified variant could play a role in gene therapies that require high accuracy and precision.
Researchers have found that the FHL1 protein plays a key role in chikungunya virus replication and pathogenesis.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A study has shown that CRISPR can be used as a regenerative technique to treat Duchenne muscular dystrophy, which could be developed as a therapeutic option for humans.
CRISPR is the buzzword of the moment in the drug discovery industry – mainly due to its potential to correct disease-causing mutations. However, those using the technology need to be mindful that it is used responsibly, and possible risks are considered before use. Mark Behlke discusses the potential of CRISPR…